samedan logo
 
 
 
spacer
home > ebr > spring 2021 > beyond cold
PUBLICATIONS
European Biopharmaceutical Review

Beyond Cold

Without a doubt, 2020 was an unusual year. The SARSCoV-2 pandemic reshaped how we work, live, learn, and interact at every level. The global response, however, was unprecedented. The imperative to contain the virus pushed the vaccine industry into the public spotlight and the outcome was disruptive: a new generation of vaccines emerged that has redefined immunisation strategies.

A New Era in Vaccine Storage

Vaccines based on novel mRNA and viral vector technologies are in line to bring the world back to normalcy. Developed, tested, and approved in record time, these vaccines have changed how industry produces, manages, and – above all – moves immunisations through the cold chain from manufacturing sites to anxiously waiting end users. Within the span of just 11 months, the transport and storage of vaccines at -70°C became a global priority. Before last year, ultra-low temperature (ULT) had only been used for the highly localised delivery of trial vaccines during Ebola outbreaks.

Until now, most vaccines were commonly stored between 2°C and 8°C worldwide. Consequently, the existing cold chain infrastructure built on standard refrigerators and freezers was insufficient to accommodate these new ULT storage needs. In anticipation and support of these new vaccine modes, and facing the largest immunisation campaign in human history, cold chain infrastructure is expanding to reach far below sub-zero temperatures and adding storage facilities to accommodate massive numbers of doses.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Alex Esmon is Senior Director/General Manager for Cold Storage at the laboratory products division of Thermo Fisher Scientific. With a PhD in Molecular Biology from the University of Missouri, Columbia, US, Dr Esmon has over 13 years of experience in industry and has overseen almost all aspects of managing products for cold storage and cryopreservation.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Owen Mumford Launches New 2-Step Single-Use Auto-Injector Platform Aidaptus®

OXFORD, England, 22nd September - Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd. has launched its new Aidaptus® auto-injector platform following successful completion of development. Aidaptus is a 2-step, spring-powered, single use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features stopper sensing technology with a self-adjusting plunger that automatically adapts to the individual stopper positions and different fill volumes in each syringe, with no change parts required. The auto-injector is available with two different spring strengths to accommodate a variety of drug viscosities.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement